Transcript of protein kinase A knock-down modulates feeding behavior and neuropeptide Y gene expression in phenylpropanolamine-treated rats

Physiological Genomics

Volumn 31, Issue 2, 2007, Pages 306-314

  Hsieh, Yih Shou ^a   Yang, Shun Fa ^a   Chu, Shu Chen ^b   Kuo, Dong Yih ^a  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b CENTRAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

Author keywords

Anorectic agent; Antisense oligonucleotide; Appetite; Hypothalamus; Signal transduction

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; NEUROPEPTIDE Y; OLIGODEOXYNUCLEOTIDE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; FEEDING BEHAVIOR; FOOD INTAKE; GENE EXPRESSION; GENE REPRESSION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANOREXIA; APPETITE DEPRESSANTS; BODY WEIGHT; CYCLIC AMP; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYCLIC AMP-DEPENDENT PROTEIN KINASES; FEEDING BEHAVIOR; GENE EXPRESSION REGULATION; GENE TARGETING; HYPOTHALAMUS; INJECTIONS, INTRAVENTRICULAR; MALE; NEUROPEPTIDE Y; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; PHENYLPROPANOLAMINE; PRO-OPIOMELANOCORTIN; PROTEIN BIOSYNTHESIS; RATS; RNA, MESSENGER; TRANSCRIPTION, GENETIC;

RATTUS;

EID: 35548990691     PISSN: 10948341     EISSN: 15312267     Source Type: Journal    
DOI: 10.1152/physiolgenomics.00110.2007     Document Type: Article

References (63)

1. Akabayashi A, Zaia CT, Gabriel SM, Silva I, Cheung WK, Leibowitz SF. Intracerebroventricular injection of dibutyryl cyclic adenosine 3′,5′-monophosphate increases hypothalamic levels of neuropeptide Y. Brain Res 660: 323-328, 1994.
2. Alexander M, Rothman RB, Baumann MH, Endres CJ, Brasic JR, Wong DF. Noradrenergic and dopaminergic effects of (+)-amphetamine-like stimulants in the baboon Papio anubis. Synapse 56: 94-9, 2005.
3. Allen JM, Yeats JC, Adrian TE, Bloom SR. Radioimmunoassay of Neuropeptide Y. Regul Pept 8: 61-70, 1984.
4. Andersson M, Konradi C, Cenci MA. cAMP response element-binding protein is required for dopamine-dependent gene expression in the intact but not the dopamine-denervated striatum. J Neurosci 21: 9930-9943, 2001.
5. Arora S, Anubhuti. Role of neuropeptides in appetite regulation and obesity. Neuropeptides 40: 375-401, 2006.
6. Billington CJ, Briggs JE, Harker S, Grace M, Levine AS. Neuropeptide Y in hypothalamic paraventricular nucleus: a center coordinating energy metabolism. Am J Physiol Regul Integr Comp Physiol 266: R1765-R1770, 1994.
7. Borovicka MC, Fuller MA, Konicki PE, White JC, Steele VM, Jaskiw GE. Phenylpropanolamine appears not to promote weight loss in patients with schizophrenia who have gained weight during clozapine treatment. J Clin Psychiatry 63: 345-348, 2002.
8. Boutillier AL, Gaiddon C, Lorang D, Roberts JL, Loeffler JP. Transcriptional activation of the proopiomelanocortin gene by cyclic AMP-responsive element binding protein. Pituitary 1: 33-43, 1998.
9. Brenhouse HC, Howe ML, Stellar JR. Differential activation of cAMP response element binding protein in discrete nucleus accumbens subregions during early and late cocaine sensitization. Behav Neurosci 121: 212-217, 2007.
10. Chance WT, Sheriff S, Balasubramaniam A. Antagonism of NPY-induced feeding by pretreatment with cyclic AMP response element binding protein antisense oligonucleotide. Neuropeptides 34: 167-172, 2000.
11. Chen PN, Chu SC, Chiou HL, Kuo WH, Chiang CL, Hsieh YS. Mulberry anthocyanins, cyanidin 3-rutinoside and cyaniding 3-glucoside, exhibited an inhibitory effect on the migration and invasion of a human lung cancer cell line. Cancer Lett 235: 248-259, 2006.
12. Cheng JT, Kuo DY. Both α1-adrenergic and D1-dopaminergic neurotransmissions are involved in phenylpropanolamine-mediated feeding suppression in mice. Neurosci Lett 347: 136-138, 2003.
13. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159, 1987.
14. Cooper TV, Klesges RC, Debon MW, Zbikowski SM, Johnson KC, Clemens LH. A placebo controlled randomized trial of the effects of phenylpropanolamine and nicotine gum on cessation rates and postcessation weight gain in women. Addict Behav 30: 61-75, 2005.
15. Das S, Grunert M, Williams L, Vincent SR. NMDA and D1 receptors regulate the phosphorylation of CREB and the induction of c-fos in striatal neurons in primary culture. Synapse 25: 227-233, 1997.
16. Diepvens K, Westerterp KR, Westerterp-Plantenga MS. Obesity and thermogenesis related to the consumption of caffeine, ephedrine, capsaicin, and green tea. Am J Physiol Regul Integr Comp Physiol 292: R77-R85, 2007.
17. Ghosh MK, Cohen JS. Oligodeoxynucleotides as antisense inhibitors of gene expression. Prog Nucleic Acid Res Mol Biol 42: 79-126, 1992.
18. Griffioen G, Thevelein JM. Molecular mechanisms controlling the localization of protein kinase A. Curr Genet 41: 199-207, 2002.
19. Hein L. Adrenoceptors and signal transduction in neurons. Cell Tissue Res 326: 541-551, 2006.
20. Higuchi H, Yang HYT, Sabol SL. Rat neuropeptide Y precursor gene expression: mRNA structure, tissue distribution, and regulation by glucocorticoids, cyclic AMP, and phorbol ester. J Biol Chem 263: 6288-6295, 1988.
21. Hsieh YS, Hsu JD, Yang SF, Kuo DY. Immunohistochemical and genomic evidence for the involvement of hypothalamic neuropeptide Y in phenylpropranolamine-mediated appetite suppression. Peptides 25: 2155-2161, 2004.
22. Hsieh YH, Yang SF, Chiou HL, Kuo DY. Transcriptional involvement of protein kinase C-alpha isozyme in amphetamine-mediated appetite suppression. Eur J Neurosci 22: 715-723, 2005.
23. Hsieh YH, Yang SF, Chiou HL, Kuo DY.Roles of central catecholamine and hypothalamic neuropeptide Y genome in the development of tolerance to phenylpropanolamine-mediated appetite suppression. Behav Neurosci. In press.
24. Hsieh YH, Yang SF, Kuo DY. Intracerebral administration of protein kinase A or c-AMP response element binding protein antisense oligonucleiotide can modulate amphetamine-mediated appetite suppression in free moving rats. Am J Physiol Endocrinol Metab 292: E123-E131, 2007.
25. Hull KM, Sanderson WD, Maher TJ. Effect of phenylpropanolamine and related compounds on beta-adrenoceptor-induced activation of adenylyl cyclase. Life Sci 52: 1287-1294, 1993.
26. Hulsey MG, Pless CM, White BD, Martin RJ. ICV administration of anti-NPY antisense oligonucleotide: effects on feeding behavior, body weight, peptide content and peptide release. Regul Pept 59: 207-214, 1995.
27. Itoi K, Horiba N, Tozawa F, Sakai Y, Sakai K, Abe K, Demura H, Suda T. Major role of 3′,5′-cyclic adenosine monophosphate-dependent protein kinase A pathway in corticotropin-releasing factor gene expression in the rat hypothalamus in vivo. Endocrinology 137: 2389-2396, 1996.
28. Kacew S, Narbaitz R, Stevenson AJ. The effects of chlorphentermine and phentermine on certain metabolic parameters associated with development of rat kidney and liver. Chem Biol Interact 19: 61-76, 1977.
29. Kalra SP, Kalra PS. To subjugate NPY is to improve the quality of life and live longer. Peptides 28: 413-418, 2007.
30. Kim RY, Shin SW, Kim BJ, Lee W, Baik JH. Dynamic regulation of hypothalamic neuropeptide gene expression and food intake by melanocortin analogues and reversal with melanocortin-4 receptor antagonist. Biochem Biophys Res Commun 329: 1178-1185, 2005.
31. 2+ signaling via protein kinase A and N-type channel-dependent mechanisms and cross-talk with leptin and orexin. Diabetes 52: 948-956, 2003.
32. Kohno D, Nakata M, Maekawa F, Fujiwara K, Maejima Y, Kuramochi M, Shimazaki T, Okano H, Onaka T, Yada T. Leptin suppresses ghrelin-induced activation of neuropeptide Y neurons in the arcuate nucleus via phosphatidylinositol 3-kinase- and phosphodiesterase 3-mediated pathway. Endocrinology 148: 2251-2263, 2007.
33. Kotz CM, Briggs JE, Grace MK, Levine AS, Billington CJ. Divergence of the feeding and thermogenic pathways influenced by NPY in the hypothalamic PVN of the rat. Am J Physiol Regul Integr Comp Physiol 275: R471-R477, 1998.
34. Kovalovsky D, Refojo D, Liberman AC, Hochbaum D, Pereda MP, Coso OA, Stalla GK, Holsboer F, Arzt E. Activation and induction of NUR77/NURR1 in corticotrophs by CRH/cAMP: involvement of calcium, protein kinase A, and MAPK pathways. Mol Endocrinol 16: 1638-1651, 2002.
35. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with folin phenol reagent. J Biol Chem 193: 265-275, 1951.
36. Magni P, Barnea A. Forskolin and phorbol ester stimulation of neuropeptide Y (NPY) production and secretion by aggregating fetal brain cells in culture: evidence for regulation of NPY biosynthesis at transcriptional and posttranscriptional levels. Endocrinology 130: 976-984, 1992.
37. Menyhert J, Wittmann G, Hrabovszky E, Keller E, Liposits Z, Fekete C. Interconnection between orexigenic neuropeptide Y- and anorexigenic alpha-melanocyte stimulating hormone-synthesizing neuronal systems of the human hypothalamus. Brain Res 1076: 101-105, 2006.
38. Mersfelder TL. Phenylpropanolamine and stroke: the study, the FDA ruling, the implications. Cleve Clin J Med 68: 208-209, 213-219, 223, 2001.
39. Mori Y, Higuchi M, Masuyama N, Gotoh Y. Adenosine A2A receptor facilitates calcium-dependent protein secretion through the activation of protein kinase A and phosphatidylinositol-3 kinase in PC12 cells. Cell Struct Funct 29: 101-110, 2004.
40. Morris BJ. Neuronal localization of neuropeptide Y gene expression in rat brain. J Comp Neurol 290: 358-368, 1989.
41. Nelson DL, Gehlert DR. Central nervous system biogenic amine targets for control of appetite and energy expenditure. Endocrine 29: 49-60, 2006.
42. Ogawa S, Brown HE, Okano HJ, Pfaff DW. Cellular uptake of intracerebrally administered oligodeoxynucleotides in mouse brain. Regul Pept 59: 143-149, 1995.
43. Ogawa S, Pfaff DW. Current status of antisense DNA methods in behavioral studies. Chem Senses 23: 249-255, 1998.
44. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates (2nd ed.) Sydney, Australia: Academic Press, 1986.
45. Rauggi R, Scheggi S, Cassanelli A, De Montis MG, Tagliamonte A, Gambarana C. The mesolimbic dopaminergic response to novel palatable food consumption increases dopamine-D1 receptor-mediated signalling with complex modifications of the DARPP-32 phosphorylation pattern. J Neurochem 92: 867-877, 2005.
46. Richard D. Exercise and the neurobiological control of food intake and energy expenditure. Int J Obes 19: S73-S79, 1995.
47. Ritter RC, Slusser PG, Stone S. Glucoreceptors controlling feeding and blood glucose: location in the hindbrain. Science 213: 451-452, 1981.
48. Roseberry AG, Liu H, Jackson AC, Cai X, Friedman JM. Neuropeptide Y-mediated inhibition of proopiomelanocortin neurons in the arcuate nucleus shows enhanced desensitization in ob/ob mice. Neuron 41: 711-722, 2004.
49. Saito SY, Maruyama Y, Kamiyama S, Nakahata N, Ohizumi Y. Ephedrae herba in Mao-Bushi-Saishin-To inhibits IgE-mediated histamine release and increases cAMP content in RBL-2H3 cells. J Pharm Sci 95: 41-46, 2004.
50. Schteingart DE. Effectiveness of phenylpropanolamine in the management of moderate obesity. Int J Obes 16: 487-493, 1992.
51. Seeley RJ, Drazen DL, Clegg DJ. The critical role of the melanocortin system in the control of energy balance. Annu Rev Nutr 24: 133-149, 2004.
52. Sheriff S, Chance WT, Fischer JE, Balasubramaniam A. Neuropeptide Y treatment and food deprivation increase cyclic AMP response element-binding in rat hypothalamus. Mol Pharmacol 51: 597-604, 1997.
53. Sheriff S, Chance WT, Iqbal S, Rizvi TA, Xiao C, Kasckow JW, Balasubramaniam A. Hypothalamic administration of cAMP agonist/PKA activator inhibits both schedule feeding and NPY-induced feeding in rats. Peptides 24: 245-254, 2003.
54. Stier BG, Hennekens CH. Phenylpropanolamine and hemorrhagic stroke in the Hemorrhagic Stroke Project: a reappraisal in the context of science, the Food and Drug Administration, and the law. Ann Epidemiol 16: 49-52, 2006.
55. Svenningsson P, Nishi A, Fisone G, Girault JA, Nairn AC, Greengard P. DARPP-32: an integrator of neurotransmission. Annu Rev Pharmacol Toxicol 44: 269-296, 2004.
56. Tasken K, Skalhegg BS, Tasken KA, Solber R, Knutsen HK, Levy FO, Sandberg M, Orstavik S, Larsen T, Johansen AK, Vang T, Schrader HP, Reinton NT, Torgersen KM, Hansson V, Jahnsen T. Structure, function, and regulation of human cAMP-dependent protein kinases. Adv Second Messenger Phosphoprotein Res 31: 191-204, 1997.
57. Vansal SS, Feller DR. Direct effects of ephedrine isomers on human beta-adrenergic receptor subtypes. Biochem Pharmacol 58: 807-810, 1999.
58. Wahlestedt C. Antisense oligonucleotide strategies in neuropharmacology. Trends Pharmacol Sci 15: 42-46, 1994.
59. Wellman PJ, Davies BT. Reversal of cirazoline- and phenylpropanolamine-induced anorexia by the α1-adrenergic receptor antagonist prazosin. Pharmacol Biochem Behav 42: 97-100, 1992.
60. Whitesell L, Geselowitz D, Chavany C, Fahmy B, Walbridge S, Alger JR, Neckers LM. Stability, clearance, and disposition of intraventricularly administered oligodeoxynucleotides: implications for therapeutic application within the central nervous system. Proc Natl Acad Sci USA 90: 4665-4669, 1993.
61. Woods SC, Figlewicz DP, Madden L, Porte D Jr, Sipols AJ, Seeley RJ. NPY and food intake: discrepancies in the model. Regul Pept 75: 403-408, 1998.
62. Yee F, Ericson H, Reis DJ, Wahlestedt C. Cellular uptake of intracerebroventricularly administered biotin- or digoxigenin-labeled antisense oligodeoxynucleotides in the rat. Cell Mol Neurobiol 14: 475-486, 1994.
63. Zhang M, Creese I. Antisense oligodeoxynucleotide reduces brain dopamine D2 receptors: behavioral correlates. Neurosci Lett 161: 223-226, 1993.